Loading market dashboard
GSK plc
GSKHealthcareNYSEGB
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Longspur Research has initiated coverage of Gelion PLC (AIM:GELN, OTC:GELNF, FRA:X0S), the battery materials company, with a central case valuation of 153p...
The UK's benchmark FTSE 100 index fell to its lowest level in more than two weeks on Thursday, weighed down by sharp declines in Asia-focused lenders and miners after reports of tighter offshore banking restrictions in China. Lower crude oil prices also dragged energy stocks lower, adding to the market's weakness.
Jefferies has flagged four near-term catalysts in GSK PLC's (LSE:GSK, NYSE:GSK) oncology pipeline following a fireside chat with the pharmaceutical...
Jefferies has flagged four near-term catalysts in GSK PLC's (LSE:GSK, NYSE:GSK) oncology pipeline following a fireside chat with the pharmaceutical company's global head of oncology and research and development at the bank's New York healthcare conference, reiterating its buy rating and 2,500p price target on the stock. GSK, which is trading at 1,872p, plans to present additional datasets for its B7H3 antibody-drug conjugate.
Gunnison Copper Corp (TSX:GCU, OTCQB:GCUMF, FRA:3XS0) has announced plans for a district-wide drilling program at its Gunnison copper project, including the...
GSK plc (GSK) Presents at Jefferies Global Healthcare Conference 2026 Transcript
GSK's Specialty Medicines business is the company's primary growth driver, supported by HIV leadership, new drug launches and a deep late-stage pipeline.
UBS has described the UK equity market as an "incomplete plate rather than an empty one" in its latest monthly strategy note, concluding that disciplined stock selection rather than broad index exposure is the right approach. The bank's REVS framework, which assesses regime, earnings, valuation and sentiment across a two to six month tactical horizon, assigns the UK market a fragile score, one notch below constructive, with earnings now the strongest supportive pillar and sentiment the most significant drag.
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?
Citi is holding back from recommending GSK PLC (LSE:GSK, NYSE:GSK) shares despite a significant clinical breakthrough in hepatitis B treatment, arguing that...
Citi is holding back from recommending GSK PLC (LSE:GSK, NYSE:GSK) shares despite a significant clinical breakthrough in hepatitis B treatment, arguing that unanswered commercial questions mean any value from the new drug is unlikely to materialise for shareholders in the near term. The bank maintains its 'neutral' rating on GSK after trial results for the company's experimental drug bepirovirsen were published in the New England Journal of Medicine.
Sonoro Gold Corp (TSX-V:SGO, OTCQB:SMOFF, FRA:23SP) said on Friday that it has increased the size of its previously announced non-brokered private placement...
GSK (GSK) may have just strengthened the investment case around one of its most important pipeline assets. Late-stage data showed bepirovirsen, its experimental
GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment Transcript
Drug candidate bepirovirsen helped nearly a fifth of patients in two late-stage clinical trials achieve a functional cure, the company said.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). Results from the two Phase 3 trials, B-Well 1 and B-Well 2, were simultaneously published in the New England Journal of Medicine and presented at the European Association for the Study of the Liver (EASL) congress. GSK licensed bepirovirsen from Ionis an.
GSK said its experimental chronic hepatitis B drug helped nearly one in five patients achieve a functional cure in late-stage studies, raising hopes for a finite treatment course as an alternative to lifelong antiviral pills.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK shares slide after Q1 despite earnings and sales beats, as investors weigh slowing legacy drug sales against strong Specialty Medicines growth.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
/PRNewswire/ -- USA News Group News Commentary - For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody
A clutch of heavyweight dividend payments knocked almost 20 points off the FTSE 100 on Thursday, with four of the index's biggest companies trading ex-dividend. HSBC Holdings PLC (LSE:HSBA) had the largest impact, removing 5.36 points from the blue-chip index as the shares traded without entitlement to the bank's latest 10-cent quarterly payout.
GSK on Monday said it had entered into a strategic collaboration with Hong Kong-listed Sino Biopharmaceutical to accelerate the launch of its hepatitis B treatment bepirovirsen in mainland China.
PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults.
Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong guidance—that could serve as a sorely needed tailwind for the healthcare sector.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bank sits 5-10% below consensus on core earnings from 2027, citing need for pipeline success and new launch execution JP Morgan has retained its underweight...
Bank sits 5-10% below consensus on core earnings from 2027, citing need for pipeline success and new launch execution JP Morgan has retained its underweight rating on GSK PLC (LSE:GSK, NYSE:GSK) with a June 2027 price target of £17, arguing that near-term earnings upgrade potential is limited and that the pharmaceutical group's longer-term outlook remains contingent on pipeline success and the execution of new product launches. Analyst Zain Ebrahim made modest forecast changes following GSK's first-quarter 2026 results, including foreign exchange-related adjustments of 0% to 1% to sales forecasts across 2026 to 2031 and upgrades of 1% to 2% to core operating profit estimates.
Ideal Power Inc (NASDAQ:IPWR, FRA:5ILA), developer of its B-TRAN bidirectional semiconductor power switch, said management will host a conference call on...
OTC Markets Group Inc. (OTCQX:OTCM) announced that Charlotte’s Web Holdings, a botanical wellness innovation company, has qualified to trade on the OTCQX...
GSK plc (GSK) Q1 2026 Earnings Call Transcript
GSK Q1 earnings and revenues beat estimates as Specialty Medicines lifted sales, with HIV, oncology and respiratory growth. The guidance for 2026 remains unchanged.
GSK (GSK) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.13 per share a year ago.
Britain's largest drugmakers saw 2026 get off on a positive note, with AstraZeneca and GSK both reporting core earnings ahead of expectations on Wednesday The CEOs of a number of European pharma giants have recently said that Europe risks losing out on new medicines as drug prices in the U.S. market are tied to lower prices elsewhere under Trump's MFN policy.
GSK PLC (LSE:GSK, NYSE:GSK), the FTSE 100 pharmaceuticals giant, has reiterated its full-year 2026 guidance after delivering a strong first quarter, with core operating profit growth and earnings per share both expected to rise between 7% and 9% at constant exchange rates. Turnover growth is forecast to be between 3% and 5%, supported by expectations of low double-digit growth in Specialty Medicines, offset by low single-digit declines to stable performance in both Vaccines and General Medicines.
The pharmaceutical giant said core operating profit for the first quarter was £2.65 billion compared with £2.53 billion for the same period a year earlier.
British drugmaker GSK reported first-quarter profit above analysts' expectations on Wednesday, helped by strong sales of its respiratory and other general medicines.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of adults with chronic hepatitis B (CHB). The FDA has granted bepirovirsen Breakthrough Therapy designation and set a Prescription Drug User Fee Act (PDUFA) target action date of October 26, 2026. “.
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK PLC's (LSE:GSK, NYSE:GSK) oncology subsidiary TESARO has secured a partial legal victory after a Delaware court dismissed a counterclaim brought by...
88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ) has tightened its contractual position at Project Phoenix in Alaska while giving joint venture...
Bango PLC (AIM:BGO, OTCQX:BGOPF), the payments and subscriptions technology company, has set a target for its subscriptions division to achieve positive...
GSK PLC's (LSE:GSK, NYSE:GSK) oncology subsidiary TESARO has secured a partial legal victory after a Delaware court dismissed a counterclaim brought by AnaptysBio, the US biotechnology company, in a dispute over the licence for cancer drug dostarlimab. The Delaware Chancery Court granted TESARO's motion to dismiss AnaptysBio's claim for anticipatory breach, though the ruling does not address the core contractual dispute between the parties.
Shares of GSK PLC Sponsored ADR (NYSE: GSK - Get Free Report) have been assigned a consensus recommendation of "Reduce" from the ten analysts that are currently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and one has issued a buy
The FTSE 100 Index pulled back this week as the US-Iran war continued and after the UK published a hot consumer inflation report. It dropped to £10,365 from this month's high of £10,687.
The FTSE 100 Index pulled back for three consecutive days as companies exposed to the ongoing US-Iran war slipped and as the UK published a strong inflation report. It also dropped as market participants waited for the upcoming UK corporate earnings.
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business.
GSK maintains a 'Strong Buy' rating, driven by robust Oncology portfolio growth and promising pipeline catalysts. The company's BLENREP is regaining traction in multiple myeloma, outperforming JNJ's DARZALEX in OS and potential label expansions to 2nd/1st-line settings. Mo-Rez [B7-H4 ADC] posted impressive phase 1 response rates in endometrial and platinum-resistant ovarian cancers, supporting five global pivotal phase 3 trials in 2026.
GSK PLC Sponsored ADR (NYSE: GSK - Get Free Report) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling 16,061,751 shares, an increase of 29.7% from the March 15th total of 12,381,329 shares. Approximately 0.9% of the company's shares are sold short. Based on
Airlines are cutting global flight schedules for April and May as Iran-driven energy disruptions elevate fuel costs and operational uncertainty. Tesla (TSLA) secured its first European approval for Full Self-Driving Supervised in the Netherlands, signaling potential for broader EU adoption.
British drugmaker GSK's experimental targeted cancer drug Mo-rez has blockbuster potential, its head of oncology research has told reporters, after early data showed the drug helped shrink tumors in patients with advanced, hard-to-treat cancers.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Douglas Lane and Associates LLC reduced its position in GSK PLC Sponsored ADR (NYSE: GSK) by 6.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,044,790 shares of the pharmaceutical company's stock after selling 76,109 shares during the quarter. Douglas Lane and
Generic versions of the drug will still be available to treat a rare genetic condition.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support Plans further investments to add capabilities and strengthen long-term operations at the Rockville site INCHEON, South Korea and ROCKVILLE, MD., March 31, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company's first manufacturing presence in the United States.
GSK plc (GSK) Presents at Goldman Sachs 9th Annual Biopharma Innovation Summit Transcript
Shore Capital has reiterated its buy recommendation on GSK PLC (LSE:GSK, NYSE:GSK) with a fair value of 2,500p, arguing the pharmaceutical group's shares are too cheap given the scale of its growth ambitions and that two of the market's main concerns about the business are beginning to fade. The broker's analyst, Dr Sean Conroy, said GSK, which has a market capitalisation of around £79 billion, trades at 14 times his 2026 earnings estimate and 12 times his 2027 forecast, a level he described as undemanding relative to peers on comparable growth.
GSK secures Japan orphan drug status for risvutatug rezetecan in SCLC, adding to multiple global designations backed by promising early data.
